Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer.

被引：0
|
作者：
Uboha, Nataliya Volodymyrivna
Eickhoff, Jens C.
Maloney, James D.
McCarthy, Daniel
DeCamp, Malcolm
Deming, Dustin A.
LoConte, Noelle K.
Matkowskyj, Kristina A.
Patel, Monica Arun
Hurst, Newton
Kratz, Jeremy D.
Lubner, Sam Joseph
Bassetti, Michael Frederick
机构：
[1] UW Carbone Canc Ctr, Madison, WI USA
[2] Univ Wisconsin, Dept Biostat, Madison, WI USA
[3] Univ Wisconsin, Div Cardiothorac Surg, Dept Surg, Madison, WI USA
[4] Univ Wisconsin, Madison, WI USA
[5] ECOG ACRIN, Madison, WI USA
[6] Univ Michigan, Ann Arbor, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4034
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III "PREVENT" trial of the AIO/CAOGI/ACO
    Bankstahl, U. S.
    Al-Batran, S-E.
    Piso, P.
    Lorenzen, S.
    Ostrzyzek, M.
    Pauligk, C.
    Habibzade, T.
    Schenk, M.
    Schlenska-Lange, A.
    Reim, D.
    Bechstein, W. O.
    Koenigsrainer, A.
    Moenig, S. P.
    Rau, B.
    Schwarzbach, M.
    Goetze, T. O.
    ANNALS OF ONCOLOGY, 2021, 32 : S1075 - S1075
  • [32] MONEO: Phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC)
    Alsina, M.
    Ponz-Sarvise, M.
    Garcia, D. Lopez
    Villacampa, G.
    De Andrea, C.
    Ochoa, C.
    Lopez-Janeiro, A.
    Jimenez-Fonseca, P.
    Arrazubi, V.
    Garcia, M. Diez
    Sanz-Garcia, E.
    de Castro, E. Martinez
    Sanchez, R. Guardeno
    Campos, M. Calvo
    Sanchez, C. Buges
    Longo, F.
    Navarro, V.
    Gros, A.
    Vivancos, A.
    Tabernero, J.
    Munoz, S.
    Melero, I.
    ANNALS OF ONCOLOGY, 2023, 34 : S2 - S3
  • [33] Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.
    Katz, Matthew H. G.
    Varadhachary, Gauri R.
    Bauer, Todd W.
    Acquavella, Nicolas
    Merchant, Nipun B.
    Le, Tri Minh
    Javle, Milind M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).
    Alsina, Maria
    Ponz-Sarvise, Mariano
    Garcia, Dario Lopez
    Gonzalez, Marta
    De Andrea, Carlos E.
    Gros, Alena
    Vivancos, Ana
    Jimenez-Fonseca, Paula
    Garcia, Marc Diez
    Arrazubi, Virginia
    Sanz-Garcia, Enrique
    de Castro, Eva Martinez
    Guardeno, Raquel
    Calvo, Mariona
    Buges, Cristina
    Longo, Federico
    Tabernero, Josep
    Villacampa, Guillermo
    Munoz, Susana
    Melero, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
    Janjigian, Yelena Y.
    Vakiani, Efsevia
    Ku, Geoffrey Y.
    Herrera, Jessica M.
    Tang, Laura H.
    Bouvier, Nancy
    Viale, Agnes
    Socci, Nicholas D.
    Capanu, Marinela
    Berger, Michael
    Ilson, David H.
    PLOS ONE, 2015, 10 (08):
  • [36] Phase II multicenter trial of docetaxel plus oxaliplatin in stage IV gastroesophageal and/or stomach cancer.
    Richards, D. A.
    Wilfong, L.
    Reznick, D.
    McCollum, D.
    Boehm, K. A.
    Zhan, F.
    Asmar, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 195S - 195S
  • [37] Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III "PREVENT" trial of the AIO /CAOGI /ACO.
    Goetze, Thorsten Oliver
    Piso, Pompiliu
    Lorenzen, Sylvie
    Bankstahl, Ulli Simone
    Ostrzyzek, Marcin
    Pauligk, Claudia
    Habibzade, Timursah
    Reim, Daniel
    Bechstein, Wolf Otto
    Konigsrainer, Alfred
    Monig, Stefan Paul
    Rau, Beate
    Schwarzbach, Matthias
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer
    Spigel, David R.
    Bendell, Johanna C.
    McCleod, Michael
    Shipley, Dianna L.
    Arrowsmith, Edward
    Barnes, E. Kirk
    Infante, Jeffrey R.
    Burris, Howard A., III
    Greco, F. Anthony
    Hainsworth, John D.
    CLINICAL COLORECTAL CANCER, 2012, 11 (01) : 45 - 52
  • [39] A randomized multicenter phase Ib/II study to assess the safety and the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab (anti-PD1) to CRT alone in patients with resectable or borderline resectable pancreatic cancer.
    Katz, Matthew H. G.
    Bauer, Todd W.
    Varadhachary, Gauri R.
    Petroni, Gina R.
    Bullock, Timothy
    Slingluff, Craig L.
    Rahma, Osama E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Phase III randomized controlled trial comparing chemotherapy to best supportive care in advanced esophageal and gastroesophageal junction cancer.
    Noronha, Vanita
    Patil, Vijay Maruti
    Menon, Nandini Sharrel
    Singh, Ajaykumar
    Chopade, Sunil Ramdhan
    Janu, Amit
    Purandare, Nilendu
    Kumar, Rajeev
    Goud, Supriya
    More, Sucheta
    Shah, Srushti
    Vairage, Reshma
    Yadav, Akanksha
    Nakti, Dipti
    Mudliya, Chetan
    Kamble, Saurabh
    Chavan, Shital
    Sonawane, Sonali
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345